Therapeutic potential of CBD in Autism Spectrum Disorder.

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by persistent deficits in social communication and interaction, as well as restricted and repetitive patterns of behavior. Despite extensive research, effective pharmacological interventions for ASD remain limited. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has potential therapeutic effects on several neurological and psychiatric disorders. CBD interacts with the endocannabinoid system, a complex cell-signaling system that plays a crucial role in regulating various physiological processes, maintaining homeostasis, participating in social and behavioral processing, and neuronal development and maturation with great relevance to ASD. Furthermore, preliminary findings from clinical trials indicate that CBD may have a modulatory effect on specific ASD symptoms and comorbidities in humans. Interestingly, emerging evidence suggests that CBD may influence the gut microbiota, with implications for the bidirectional communication between the gut and the central nervous system. CBD is a safe drug with low induction of side effects. As it has a multi-target pharmacological profile, it becomes a candidate compound for treating the central symptoms and comorbidities of ASD.

A journey through cannabidiol in Parkinson's disease.

Parkinson's disease is a chronic neurodegenerative disorder with no known cure characterized by motor symptoms such as tremors, rigidity, bradykinesia (slowness of movement), and postural instability. Non-motor symptoms like cognitive impairment, mood disturbances, and sleep disorders often accompany the disease. Pharmacological treatments for these symptoms are limited and frequently induce significant adverse reactions, underscoring the necessity for appropriate treatment options. Cannabidiol is a phytocannabinoid devoid of the euphoric and cognitive effects of tetrahydrocannabinol. The study of cannabidiol's pharmacological effects has increased exponentially in recent years. Preclinical and preliminary clinical studies suggest that cannabidiol holds therapeutic potential for alleviating symptoms of Parkinson's disease, offering neuroprotective, anti-inflammatory, and antioxidant properties. However, knowledge of cannabidiol neuromolecular mechanisms is limited, and its pharmacology, which appears complex, has not yet been fully elucidated. By examining the evidence, this review aims to provide and synthesize scientifically proven evidence for the potential use of cannabidiol as a novel treatment option for Parkinson's disease. We focus on studies that administrated cannabidiol alone. The results of preclinical trials using cannabidiol in models of Parkinson's disease are encouraging. Nevertheless, drawing firm conclusions on the therapeutic efficacy of cannabidiol for patients is challenging. Cannabidiol doses, formulations, outcome measures, and methodologies vary considerably across studies. Though, cannabidiol holds promise as a novel therapeutic option for managing both motor and non-motor symptoms of Parkinson's disease, offering hope for improved quality of life for affected individuals.

Cannabidiol and pain.

Chronic pain presents significant personal, psychological, and socioeconomic hurdles, impacting over 30% of adults worldwide and substantially contributing to disability. Unfortunately, current pharmacotherapy often proves inadequate, leaving fewer than 70% of patients with relief. This shortfall has sparked a drive to seek alternative treatments offering superior safety and efficacy profiles. Cannabinoid-based pharmaceuticals, notably cannabidiol (CBD), hold promise in pain management, driven by their natural origins, versatility, and reduced risk of addiction. As we navigate the opioid crisis, ongoing research plunges into CBD's therapeutic potential, buoyed by animal studies revealing its pain-relieving prowess through various system tweaks. However, the efficacy of cannabis in chronic pain management remains a contentious and stigmatized issue. The International Association for the Study of Pain (IASP) presently refrains from endorsing cannabinoid use for pain relief. Nevertheless, evidence indicates their potential in alleviating cancer-related, neuropathic, arthritis, and musculoskeletal pain, necessitating further investigation. Crucially, our comprehension of CBD's role in pain management is a journey still unfolding, with animal studies illustrating its analgesic effects through interactions with the endocannabinoid, inflammatory, and nociceptive systems. As the plot thickens, it's clear: the saga of chronic pain and CBD's potential offers a compelling narrative ripe for further exploration and understanding.

Cannabidiol improves nonmotor symptoms, attenuates neuroinflammation and favors hippocampal newborn neuronal maturation in a rat model of Parkinsonism.

OBJECTIVE: To investigate the effects of cannabidiol (CBD) on emotional and cognitive symptoms in rats with intra-nigral 6-hydroxydopamine (6-OHDA) lesions. METHODS: Adult male Wistar rats received bilateral intranigral 6-OHDA infusions and were tested in a battery of behavioral paradigms to evaluate nonmotor symptoms. The brains were obtained to evaluate the effects of CBD on hippocampal neurogenesis. RESULTS: 6-hydroxydopamine-lesioned rats exhibited memory impairments and despair-like behavior in the novelty-suppressed feeding test and forced swim test, respectively. The animals also exhibited dopaminergic neuronal loss in the substantia nigra pars compacta (SNpc), striatum, and ventral tegmental area and a reduction of hippocampal neurogenesis. Cannabidiol decreased dopaminergic neuronal loss in the SNpc, reduced the mortality rate and decreased neuroinflammation in 6-OHDA-lesioned rats. In parallel, CBD prevented memory impairments and attenuated despair-like behavior that were induced by bilateral intranigral 6-OHDA lesions. Repeated treatment with CBD favored the neuronal maturation of newborn neurons in the hippocampus in Parkinsonian rats. CONCLUSION: The present findings suggest a potential beneficial effect of CBD on nonmotor symptoms induced by intra-nigral 6-OHDA infusion in rats.

Cannabidiol and it fluorinate analog PECS-101 reduces hyperalgesia and allodynia in trigeminal neuralgia via TRPV1 receptors.

Trigeminal neuralgia (TN) is an intense and debilitating orofacial pain. The gold standard treatment for TN is carbamazepine. This antiepileptic drug provides pain relief with limited efficacy and side effects. To study the antinociceptive potential of cannabidiol (CBD) and its fluorinated analog PECS-101 (former HUF-101), we induced unilateral chronic constriction injury of the infraorbital nerve (IoN-CCI) in male Wistar rats. Seven days of treatment with CBD (30 mg/kg), PECS-101 (3, 10, and 30 mg/kg), or carbamazepine (10 and 30 mg/kg) reduced allodynia and hyperalgesia responses. Unlike carbamazepine, CBD and PECS-101 did not impair motor activity. The relief of the hypersensitive reactions has been associated with transient receptor potential vanilloid type 1 (TRPV1) modulation in the trigeminal spinal nucleus. CBD (30 mg/kg) and PECS-101 (10 and 30 mg/kg) reversed the increased expression of TRPV1 induced by IoN-CCI in this nucleus. Using a pharmacological strategy, the combination of the selective TRPV1 antagonist (capsazepine-CPZ - 5 mg/kg) with sub-effective doses of CBD (3 and 10 mg/kg) is also able to reverse the IoN-CCI-induced allodynia and hyperalgesia responses. This effect was accompanied by reduced TRPV1 protein expression in the trigeminal spinal nucleus. Our results suggest that CBD and PECS-101 may benefit trigeminal neuralgia without motor coordination impairments. PECS-101 is more potent against the hypernociceptive and motor impairment induced by TN compared to CBD and carbamazepine. The antinociceptive effect of these cannabinoids is partially mediated by TRPV1 receptors in the caudal part of the trigeminal spinal nucleus, the first central station of orofacial pain processing.

4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.

We tested the efficacy of 4'-fluorocannabidiol (4'-F-CBD), a semisynthetic cannabidiol derivative, and HU-910, a cannabinoid receptor 2 (CB2) agonist in resolving l-DOPA-induced dyskinesia (LID). Specifically, we were interested in studying whether these compounds could restrain striatal inflammatory responses and rescue glutamatergic disturbances characteristic of the dyskinetic state. C57BL/6 mice were rendered hemiparkinsonian by unilateral striatal lesioning with 6-OHDA. Abnormal involuntary movements were then induced by repeated i.p. injections of l-DOPA + benserazide. After LID was installed, the effects of a 3-day treatment with 4'-F-CBD or HU-910 in combination or not with the TRPV1 antagonist capsazepine (CPZ) or CB2 agonists HU-308 and JWH015 were assessed. Immunostaining was conducted to investigate the impacts of 4'-F-CBD and HU-910 (with CPZ) on inflammation and glutamatergic synapses. Our results showed that the combination of 4'-F-CBD + CPZ, but not when administered alone, decreased LID. Neither HU-910 alone nor HU-910+CPZ were effective. The CB2 agonists HU-308 and JWH015 were also ineffective in decreasing LID. Both combination treatments efficiently reduced microglial and astrocyte activation in the dorsal striatum of dyskinetic mice. However, only 4'-F-CBD + CPZ normalized the density of glutamate vesicular transporter-1 (vGluT1) puncta colocalized with the postsynaptic density marker PSD95. These findings suggest that 4'-F-CBD + CPZ normalizes dysregulated cortico-striatal glutamatergic inputs, which could be involved in their anti-dyskinetic effects. Although it is not possible to rule out the involvement of anti-inflammatory mechanisms, the decrease in striatal neuroinflammation markers by 4'-F-CBD and HU-910 without an associated reduction in LID indicates that they are insufficient per se to prevent LID manifestations.

Sodium nitroprusside enhances stepping test performance and increases medium spiny neurons responsiveness to cortical inputs in a rat model of Levodopa-induced dyskinesias.

Levodopa (L-DOPA) is the classical gold standard treatment for Parkinson's disease. However, its chronic administration can lead to the development of L-DOPA-induced dyskinesias (LIDs). Dysregulation of the nitric oxide-cyclic guanosine monophosphate pathway in striatal networks has been linked to deficits in corticostriatal transmission in LIDs. This study investigated the effects of the nitric oxide (NO) donor sodium nitroprusside (SNP) on behavioural and electrophysiological outcomes in sham-operated and 6-hydroxydopamine-lesioned rats chronically treated with vehicle or L-DOPA, respectively. In sham-operated animals, systemic administration of SNP increased the spike probability of putative striatal medium spiny neurons (MSNs) in response to electrical stimulation of the primary motor cortex. In 6-hydroxydopamine-lesioned animals, SNP improved the stepping test performance without exacerbating abnormal involuntary movements. Additionally, SNP significantly increased the responsiveness of putative striatal MSNs in the dyskinetic striatum. These findings highlight the critical role of the NO signalling pathway in facilitating the responsiveness of striatal MSNs in both the intact and dyskinetic striata. The study suggests that SNP has the potential to enhance L-DOPA's effects in the stepping test without exacerbating abnormal involuntary movements, thereby offering new possibilities for optimizing Parkinson's disease therapy. In conclusion, this study highlights the involvement of the NO signalling pathway in the pathophysiology of LIDs.

The antidepressant-like effect of doxycycline is associated with decreased nitric oxide metabolite levels in the prefrontal cortex.

Doxycycline is an antibiotic that has shown neuroprotective, anti-inflammatory, and antidepressant-like effects. Low doses of doxycycline revert the behavioral and neuroinflammatory responses induced by lipopolysaccharide treatment in a mice model of depression. However, the molecular mechanisms involved in the antidepressant action of doxycycline are not yet understood. Doxycycline inhibits the synthesis of nitric oxide (NO), which increases after stress exposure. Inducible NO synthase (iNOS) inhibition also causes antidepressant-like effects in animal models sensitive to antidepressant-like effects such as the forced swimming test (FST). However, no direct study has yet investigated if the antidepressant-like effects of doxycycline could involve changes in NO-mediated neurotransmission. Therefore, this study aimed at investigating: i) the behavioral effects induced by doxycycline alone or in association with ineffective doses of a NO donor (sodium nitroprusside, SNP) or an iNOS inhibitor (1400 W) in mice subjected to the FST; and ii) doxycycline effects in NO metabolite levels in the prefrontal cortex and hippocampus these animals. Male mice (8 weeks) received i.p. injection of saline or doxycycline (10, 30, and 50 mg/kg), alone or combined with SNP (0.1, 0.5, and 1 mg/kg) or 1400 W (1, 3, and 10 µg/kg), and 30 min later were submitted to the FST. Animals were sacrificed immediately after, and NO metabolites nitrate/nitrite (NOx) were measured in the prefrontal cortex and hippocampus. Doxycycline (50 mg/kg) reduced both the immobility time in the FST and NOx levels in the prefrontal cortex of mice compared to the saline group. The antidepressant-like effect of doxycycline in the FST was prevented by SNP (1 mg/kg) pretreatment. Additionally, sub-effective doses of doxycycline (30 mg/kg) associated with 1400 W (1 µg/kg) induced an antidepressant-like effect in the FST. Altogether, our data suggest that the reducing NO levels in the prefrontal cortex through inhibition of iNOS could be related to acute doxycycline treatment resulting in rapid antidepressant-like effects in mice.

Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study / Doxiciclina no tratamento das discinesias induzidas pela doença de Parkinson: um estudo preliminar

Abstract Background Levodopa-induced dyskinesia (LID) is a common motor complication of levodopa therapy in patients with Parkinson's disease (PD). Doxycycline is a widely used and inexpensive tetracycline with anti-inflammatory properties. Objective To evaluate the efficacy and safety of doxycycline in patients with PD and LID. Methods This was an open-label, uncontrolled, single-arm, single-center, phase 2 proof-of-concept study in patients with PD with functional impact of dyskinesia, which used levodopa three times daily, in a movement disorders clinic in Brazil. Participants were treated with doxycycline 200 mg/day for 12 weeks, with evaluations at baseline, week4, and week 12 of treatment. The primary outcome measure was the change from baseline in the Unified Dyskinesia Rating Scale (UDysRS) total score at week 12, evaluated by two blinded raters. Key secondary outcomes measures were OFF time and ON time with troublesome dyskinesia in the PD home diary. Results Eight patients with PD were treated and evaluated. Doxycycline 200 mg/day reduced the UDysRS total score at week 12, compared with baseline (Friedman χ2 = 9.6; p = 0.008). Further, doxycycline reduced the ON time with troublesome dyskinesia (Friedman χ2 = 10.8; p = 0.004) without worsening parkinsonism. There were no severe adverse events, and dyspepsia was the commonest event. Conclusion In this preliminary, open-label and uncontrolled trial, doxycycline was effective in reducing LID and safe after a 12-week treatment. Further well-designed placebo-controlled clinical trials with a longer duration and a larger number of participants are needed. Clinical trial registration https://ensaiosclinicos.gov.br, identifier: RBR-1047fwbf

Resumo Antecedentes A discinesia induzida por levodopa (DIL) é uma complicação motora comum da terapia com levodopa em pacientes com doença de Parkinson (DP). A doxiciclina é uma tetraciclina amplamente usada e barata, com propriedade anti-inflamatória. Objetivo Avaliar a eficácia e segurança da doxiciclina em pacientes com DP e DIL. Métodos Este foi um estudo aberto, não-controlado, de braço único, monocêntrico, fase 2 e de prova de conceito, em pacientes com DP e impacto funcional das discinesias, que usavam levodopa três vezes ao dia, em um ambulatório de distúrbios de movimento no Brasil. Os participantes foram tratados com doxiciclina 200 mg/dia por 12 semanas, com avaliações na base, na semana 4 e na semana 12 do tratamento. A medida de desfecho primário foi a mudança no escore total da Unified Dyskinesia Rating Scale (UDysRS) da base à semana 12, avaliada por dois avaliadores cegos. As medidas-chave de desfecho secundário fora o tempo em OFF e tempo em ON com discinesia problemática. Resultados Oito pacientes com DP foram tratados e avaliados. A doxiciclina 200 mg/dia reduziu o escore total da UDysRS na semana 12, comparado com a avaliação inicial (χ2 de Friedman = 9.6; p = 0.008). Além disso, a doxiciclina reduziu o tempo em ON com discinesia problemática (χ2 de Friedman = 10.8; p = 0.004) sem piorar o parkinsonismo. Não houve eventos adversos graves, e dispepsia foi o evento mais comum. Conclusão No presente estudo preliminar, aberto e não-controlado, a doxiciclina foi eficaz em reduzir as DIL e segura após tratamento por 12 semanas. Estudos clínicos bem-desenhados e placebo-controlados adicionais, com duração mais longa e maior número de participantes, são necessários.

Biological bases for a possible effect of cannabidiol in Parkinson's disease

Current pharmacotherapy of Parkinson's disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can improve patients' quality of life with fewer side effects are needed, but not yet available. Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last decade. In this context, we aimed to critically review the literature on potential therapeutic effects of CBD in PD and discuss clinical and preclinical evidence supporting the putative neuroprotective mechanisms of CBD. We searched MEDLINE (via PubMed) for indexed articles published in English from inception to 2019. The following keywords were used: cannabis; cannabidiol and neuroprotection; endocannabinoids and basal ganglia; Parkinson's animal models; Parkinson's history; Parkinson's and cannabidiol. Few studies addressed the biological bases for the purported effects of CBD on PD. Six preclinical studies showed neuroprotective effects, while three targeted the antidyskinetic effects of CBD. Three human studies have tested CBD in patients with PD: an open-label study, a case series, and a randomized controlled trial. These studies reported therapeutic effects of CBD on non-motor symptoms. Additional research is needed to elucidate the potential effectiveness of CBD in PD and the underlying mechanisms involved.

The neuroprotective effect of doxycycline on neurodegenerative diseases

Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the "off-target" effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.

The neuroprotective effect of doxycycline on neurodegenerative diseases

Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the "off-target" effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.

Effects of aging on nitrergic neurons in human striatum and subthalamic nucleus / Efeitos do envelhecimento sobre os neurônios nitrérgicos no estriado e núcleo subtalâmico humano

Nitric oxide (NO) is a major neurotransmitter associated with motor control in basal ganglia. Movement disorders, as essential tremor and Parkinson’s disease, are more prevalent on aged individuals. We investigated the effects of aging on neuronal density and diameter/area of nitrergic neurons in samples of striatum (caudate and putamen) and subthalamic nucleus of 20 human brains from normal subjects, stained by histochemistry for NADPH-diaphorase and immunohistochemistry for neuronal NO synthase. Our data showed aging does not modify the neuronal density and size of nitrergic neurons in striatum and subthalamic nucleus. These findings suggest a lack of association between aging and morphologic changes on nitrergic neurons.

O óxido nítrico (NO) é um importante neurotransmissor associado ao controle motor nos núcleos da base. Os distúrbios de movimento, como tremor essencial e a doença de Parkinson, são mais prevalentes em indivíduos idosos. Nós investigamos os efeitos do envelhecimento sobre a densidade neuronal e diâmetro/área dos neurônios nitrérgicos em amostras de estriado (caudado e putâmen) e núcleo subtalâmico de 20 encéfalos humanos de indivíduos normais, corados pela técnica histoquímica da NADPH-diaforase e imunohistoquímica para a sintase do NO neuronal. Nossos resultados mostraram que o envelhecimento não modifica a densidade neuronal e as dimensões dos neurônios nitrérgicos no estriado e núcleo subtalâmico. Estes achados sugerem uma falta de associação entre envelhecimento e mudanças morfológicas nos neurônios nitrérgicos.

Does a small size needle puncture cause intervertebral disc changes?

PURPOSE:Small size needles have been regularly used for intradiscal injection of innocuous/potential therapeutic compounds in experimental conditions, but also in clinic procedures, such as discography. Our aim was to investigate if a 30-gauge needle could trigger observable changes on intact intervertebral discs. We compared these effects to those induced by a large size needle (21-gauge), a well-known intervertebral disc degenerative model based on needle puncture.METHODS:Coccygeal intervertebral discs (Co8-9) of adult male Wistar rats were punctured with a 21-gauge needle, while the coccygeal levels Co7-8 and Co9-10 remained intact. The 30-gauge needle was used to inject a safe volume of saline (2 µl) on both intact (Co9-10) and punctured (Co8-9) discs. MRI and histological score were performed at 2, 15 and 42 days after procedure.RESULTS: MRI analyses revealed significant reduction on signal intensity of 21-gauge punctured discs. Intact discs which received a saline injection through a 30-gauge needle also revealed significant alterations in the MRI signal when compared with control discs. No histological changes were observed in the intact saline injected discs at any time analyzed.CONCLUSION: Since significant intervertebral image changes were observed with a 30-gauge needle, cautious interpretation of the pharmacological inoculation findings is required.

Influence of external factors on the preservation of human nervous tissue for histological studies: review article / Influência dos fatores externos sobre a preservação do tecido nervoso humano nos estudos histológicos: artigo de revisão

Neuropathological studies are crucial for the new knowledge on pathophysiology and treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The postmortem brain tissue processing method directly impacts on both the appropriate integrity and the biomolecules detection by different histological and molecular biology techniques. In this review we will discuss topics on the influence of some external factors on the preservation of the brain tissue for histological studies (histochemistry and immunohistochemistry), such as factors either prior or after the death, and the chosen method for the preservation of nervous tissue. By means of a specific example, we propose a strict record of various conditions involved in the method of preservation of nervous tissue, and its correlation with variables that measure the quality of the histological sample as markers of preservation of biological material for further studies.

Os estudos neuropatológicos são fundamentais para novas descobertas sobre a fisiopatologia e o tratamento de doenças neurodegenerativas, como a doença de Alzheimer e a doença de Parkinson. O modo como o encéfalo pós-morte é processado influencia diretamente na adequada integridade e na detecção de biomoléculas por diferentes técnicas histológicas e de biologia molecular. Nesta revisão, abordaremos tópicos sobre a influência de determinados fatores externos sobre a preservação do encéfalo para estudos histológicos (histoquímica e imuno-histoquímica), como as condições anteriores e posteriores ao óbito, e o método escolhido de conservação do tecido nervoso. Por meio de um exemplo específico, propomos um rigoroso registro das diversas condições envolvidas no processo de preservação do tecido nervoso e sua correlação com variáveis que avaliam a qualidade da amostra histológica, como marcadores da preservação do material biológico para estudos posteriores..

Perfil antipsicótico do canabidiol / Antipsychotic profile of cannabidiol

O canabidiol, fitocanabinóide presente na planta Cannabis sativa é desprovido dos efeitos psicotomiméticos característicos do principal composto da Cannabis, o ∆9-tetraidrocanabinol, mais conhecido como delta 9-THC. Um conjunto crescente de evidências sugere que o canabidiol apresente potencial terapêutico para o tratamento dos sintomas de distúrbios psiquiátricos, como a depressão, a ansiedade e as psicoses. A observação em humanos, mas também em modelos animais experimentais da capacidade do canabidiol de antagonizar os efeitos psicotomiméticos do delta 9-THC constitui uma importante evidência de seu potencial para utilização clínica. Embora os efeitos farmacológicos do canabidiol tenham sido investigados em diferentes sistemas biológicos in vitro e in vivo, seu mecanismo de ação ainda não é claro. O delta 9-THC ativa os receptores canabinóides do tipo CB1 e CB2, contudo o canabidiol apresenta uma baixa afinidade por esses receptores. Adicionalmente, o canabidiol em apresentado boa tolerabilidade em testes com humanos, tornando-o alvo de grande interesse da comunidade científica. O objetivo dessa revisão é apresentar, de forma breve, algumas das principais evidências experimentais e clínicas do provável perfil antipsicótico do canabidiol...

Cannabidiol an important phytocannabinoid present in the Cannabis sativa opposing to the major plant compound D9-tetrahydrocannabinol, known as delta-9-THC, is devoid of the psychotomimetic effects. Growing set of evidence suggest that cannabidiol may be used for the treatment of the symptoms of psychiatric disorders such as depression, anxiety and psychosis. The first evidence of the cannabidiol therapeutic potential was the observation of its ability to antagonize delta-9-THC effects either on human and experimental animal models. Pharmacological effects of CBD has been investigated in different biological systems, in vitro and in vivo, however, the mechanisms responsible for their therapeutic potential are still unclear. delta-9-THC effects results from activation of the cannabinoid receptors CB1 and CB2, however, the cannabidiol has low affinity for these receptors. The good tolerability of cannabidiolin human trials makes this compound an interesting target of the scientific community. The aim of this paper is to present concisely some experimental and clinical evidence about the cannabidiol antipsychotic profile...

Modelo de degeneração do disco intervertebral por punção da cauda de ratos Wistar: avaliação histológica e radiográfica / Modelo de degeneración del disco intervertebral por punción de la cola de ratas Wistar: evaluación histológica y radiográfica / Injury model by needle puncture of the Wistar rats' tail: histological and radiographic assessments

OBJETIVO: descrever a caracterização histológica e radiográfica do método de indução da degeneração do disco intervertebral da cauda de ratos Wistar induzida por meio de punção. MÉTODOS: ratos Wistar machos adultos foram anestesiados, radiografados e submetidos à punção dos discos intervertebrais localizados entre a sexta e a sétima e a oitava e nona vértebras coccígeas. Para a punção foi utilizada agulha de 20G, que foi introduzida até o ânulo fibroso, e foi realizada dupla rotação de 360º, mantendo-se a mesma posição durante 30 segundos antes da retirada. O disco intermediário aos segmentos lesados (7-8) não foi puncionado e foi utilizado como controle. Foi selecionado o período pós-lesão de 30 dias (n=9) para sacrifício e análise dos discos intervertebrais. Os animais foram radiografados 30 dias após a lesão para análise da altura do disco intervertebral. Os segmentos da cauda foram removidos, fixados e desmineralizados, processados e corados com Hematoxilina-Eosina para avaliação histológica. RESULTADOS: a análise radiográfica revelou a redução significativa da altura dos discos lesados em relação ao controle. A avaliação histológica revelou alterações no núcleo pulposo e ânulo fibroso dos discos lesados em relação ao controle. Não foram observadas diferenças na intensidade de lesão entre os discos proximal e distal. CONCLUSÃO: a degeneração do disco intervertebral da cauda de ratos Wistar induzida por meio de punção mostrou ser método reprodutível para estudo da degeneração do disco intervertebral. Esse modelo mostrou validade para avaliação experimental de novas intervenções terapêuticas nos processos de degeneração do disco intervertebral.

OBJECTIVE: to report the induction of intervertebral disc degeneration of the rat caudal spine by needle puncture and its radiographic and histologic characterization. METHODS: adult male Wistar rats were anesthetized, submitted to the X-Ray and then to the needle puncture (20G) of intervertebral disc between the sixth and seventh (proximal segment) and the eighth and ninth (distal segment) coccygeal vertebrae. Radiographies were taken 30 days after lesion for analysis of intervertebral disc height. The intermediate disc (7-8) to injured segments was not punctured and was considered as control. All segments were removed, fixed and demineralized, processed and stained with Hematoxylin-Eosin for histological evaluation. RESULTS: radiographic analysis revealed significant reduction in disc height of lesioned discs compared to control. Similarly, histological analysis revealed significant changes in the nucleus pulposus and annulus fibrosus of the lesioned discs (proximal and distal) relative to the control. There was no difference in the intensity of injury between the proximal and distal discs. CONCLUSION: the experimental model of tail intervertebral disc degeneration by needle puncture reproduced the steps of the intervertebral disc degeneration, assessed by different instruments, and it can be used for experimental evaluation of new therapeutic interventions for intervertebral disc degeneration process.

OBJETIVO: describir la caracterización histológica y radiográfica del método de inducción de la degeneración del disco intervertebral de la cola de ratas Wistar, inducida por medio de la punción. MÉTODOS: ratas Wistar machos adultos fueron anestesiados, radiografiados y sometidos a la punción de los discos intervertebrales localizados, entre la sexta y la séptima; y la octava y novena vértebras coccígeas. Para la punción, fue utilizada una aguja de 20G, que fue introducida hasta el ánulo fibroso, y fue realizada una dupla rotación de 360º, manteniendo esta posición durante 30 segundos, previamente a la retirada. El disco intermediario a los segmentos lesionados (7-8) no fue puncionado y fue considerado como control. Fue seleccionado el periodo post-lesión de 30 días (n=9) para sacrificio y análisis de los discos intervertebrales. Los animales fueron radiografiados 30 días después de la lesión para análisis de la altura del disco intervertebral. Los segmentos de la cola fueron removidos, fijados y desmineralizados, procesados y coloreados con hematoxilina-eosina para evaluación histológica. RESULTADOS: el análisis radiográfico mostró una reducción significativa de la altura de los discos lesionados en relación al control. La evaluación histológica mostró alteraciones en el núcleo pulposo y el ánulo fibroso de los discos lesionados en relación al control. No fueron observadas diferencias en la intensidad de la lesión entre los discos proximal y distal. CONCLUSIÓNES: la degeneración del disco intervertebral de la cola de ratas Wistar inducida por medio de punción mostró ser un método reproducible para el estudio de la degeneración del disco intervertebral. Ese modelo mostró validez para la evaluación experimental de nuevas intervenciones terapéuticas en los procesos de la degeneración del disco intervertebral.

Influência da decorticação vertebral na neoformação dos tecidos da interface do enxerto ósseo / Influence of vertebral decortication on tissue neoformation at bone graft interface

OBJETIVO: Determinar a influência da decorticação dos elementos posteriores da coluna vertebral na integração do enxerto ósseo, considerando a avaliação quantitativa e qualitativa dos tecidos (ósseo, cartilaginoso e fibroso) da interface entre o leito receptor e o enxerto ósseo. MÉTODOS: Foram utilizados 24 ratos Wistar, divididos em dois grupos de acordo com a realização da decorticação do leito receptor do enxerto. Foi utilizado enxerto autólogo derivado dos processos espinhosos das duas primeiras vértebras lombares. A neoformação tecidual na interface entre o leito receptor e seu enxerto ósseo foi avaliada após três semanas por meio de análise histomorfométrica. RESULTADOS: No grupo de animais com o leito receptor decorticado a média da porcentagem de osso neoformado foi de 40 por cento±6,1, e 7,7 por cento± 3,5 no grupo não decorticado (p=0,0001). A média da porcentagem de formação do tecido cartilaginoso no grupo decorticado foi de 7,2 por cento±3,5, no não decorticado de 10,9 por cento±5,6 (p=0,1123). A formação de tecido fibroso no grupo decorticado apresentou média de 8,6 por cento±3,9 e no não decorticado e 24 por cento±10,1, (p=0,0002). CONCLUSÕES: A decorticação acelerou o processo histológico da integração do enxerto ósseo. Ocorrendo maior produção de tecido ósseo neoformado e predomínio da ossificação do tipo intramembranosa no grupo de animais nos quais a decorticação foi realizada.

OBJECTIVE: To determine the influence of vertebral posterior elements decortication in bone graft integration, considering a qualitative and quantitative evaluation of the (bone, cartilaginous, and fibrous) tissues in the interface between the receptor bed and the bone graft. METHODS: Twenty-four Wistar rats were divided into two groups according to the decortication of the bone graft receptor bed. Autologous bone graft from the first and second lumbar vertebrae were used. The new tissue formation in the interface between the receptor bed and its bone graft was evaluated after three weeks by histomorphometric analyses. RESULTS: In the animals group with the decorticated posterior bed the mean percentage of new bone formation was 40 percent±6.1, and 7.7 percent± 3.5 in the not decorticated group. A(p=0.0001). The mean percentage of cartilaginous tissue formation in the decorticated group was 7.2 percent±3.5, and in the not decorticated 10.9 percent±5.6 (p=0.1123). The fibrous tissue formation in the decorticated group presented a mean of 8.6 percent±3.9 and, in the not decorticated group, of 24 percent±10.1, with which is a statistically significant difference (p=0.0002). CONCLUSION: Decortication accelerated the histologic process of bone graft integration. More production of new bone tissue and predominance of intramembranous type of ossification occurred in the decorticated group.

O trauma raquimedular / El trauma raquimedular / The spinal cord injury

A medula espinhal dos mamíferos adultos não permite a regeneração de axônios. Por razões ainda desconhecidas, as fibras neurais falham em cruzar o sítio da lesão, como se não houvesse crescimento, desde a primeira tentativa. Quais mecanismos poderiam explicar a perda da capacidade de regeneração? As cicatrizes formadas pelas células da glia seriam uma consequência da falha na regeneração ou a causa? Diversas linhas de evidência sugerem que a regeneração da medula espinhal seria impedida no sistema nervoso central pela ação de fatores locais no sítio da lesão, e que o sistema nervoso central não-lesado é um meio permissivo para o crescimento axonal, na direção de alvos específicos. Uma vez que os axônios são induzidos adequadamente a cruzar a lesão com o auxílio de implantes, fármacos ou células indiferenciadas, as fibras em regeneração podem encontrar a via específica e estabelecer conexões corretas. O que ainda não se sabe é que combinação de moléculas induz/inibe o potencial de regeneração do tecido e que mecanismos permitem aos neurônios formarem conexões específicas com os alvos com os quais são programados a fazer.

The adult mammal spinal cord does not allow axons regeneration. For unknown reasons, the neural fibers fail in coming across the site of the lesion, as if there were no growing from the first try. What mechanisms may explain the lost of regeneration capability? Are scars formed by glial cells a consequence of regeneration fail or the cause? Several evidence lines suggest that spinal cord regeneration would be blocked in the central nervous system by actions of local factors in the site of the wound, and no injured central nervous system is a permissive way for the axonal growing into specific targets. If axons are correctly induced to cross the injury, supported by implants, drugs and undifferentiated cells, the fibers in regeneration may find a specific way to establish the right connections. The combination of molecules which induce/inhibit the regeneration potential of the tissue remains unknown, as well as the mechanisms that enable the neuron to make specific connections with targets it is programmed to connect with.

La medula espinal de los mamíferos adultos no permite la regeneración de los axones. Por razones aun no conocidas, las fibras neurales fallan en la tarea de cruzar por el sitio de la lesión, como si no hubiese crecimiento, desde el primer intento. ¿Cuáles mecanismos podrían explicar la pérdida de la capacidad de la regeneración? ¿Las cicatrices formadas por las células de la glía son una consecuencia del fallo en la regeneración o serían la causa? Diversas líneas de evidencia sugieren que la regeneración de la medula espinal sería impedida en el sistema nervioso central por la acción de factores locales en el sitio de la lesión, y que el sistema nervioso central no lesionado es un medio permisivo para el crecimiento axonal, en la dirección de dianas específicas. Una vez que los axones sean inducidos adecuadamente a cruzar la lesión, con auxilio de implantes, fármacos o células indiferenciadas, las fibras en regeneración podrían encontrar la vía específica y establecer conexiones correctas. Lo que aun es desconocido es que combinación de moléculas induce/inhibe el potencial de regeneración del tejido y cuáles mecanismos permiten a las neuronas formar conexiones específicas, con las dianas que son programadas a hacer.

Influência do estreitamento do canal vertebral e do tempo para a descompressão na recuperação locomotora de ratos / Influencia del estrechamiento del canal vertebral y del tiempo para la descompresión en la recuperación locomotora de ratas / The influence of spinal canal narrowing and timing of decompression on locomotion recovery of rats

O objetivo deste trabalho foi estudar as consequências da lesão por contusão da medula espinhal, associada ao estreitamento do canal vertebral, no comportamento motor de ratos, avaliando-se o efeito do tempo para descompressão na recuperação neurológica dos animais. Métodos: foram utilizados ratos Wistar machos (n=6 por grupo), subdivididos nos seguintes grupos experimentais: laminectomia (T9-T10, Grupo Controle), contusão por queda de peso (10 g de peso, 15 cm de altura), estreitamento do canal vertebral em 35 por cento (hastes de policarbonato; espessura de 0,78 mm) e contusão associada ao estreitamento do canal vertebral. O grupo de lesão associada foi ainda subdividido em sem ou com descompressão 24 ou 72 horas após a cirurgia. Os animais foram sacrificados sete dias após os procedimentos cirúrgicos. A função locomotora dos animais foi avaliada por meio do teste do campo aberto, do teste do plano inclinado e pela aplicação da escala BBB, antes da cirurgia, 24 e 72 horas depois da cirurgia e após 7 dias do procedimento cirúrgico. Resultados: a lesão por queda de peso e compressão da medula espinhal, bem como a lesão mista, prejudicaram o comportamento motor dos animais, sendo que a descompressão cirúrgica após 24 e 72 horas da cirurgia não melhorou a recuperação motora dos animais, como mostram os resultados da avaliação de campo aberto, no plano inclinado e pela escala BBB. Por outro lado, os animais que sofreram lesão medular por queda de peso apresentaram melhores escores na escala BBB e ângulos maiores no plano inclinado do que aqueles que sofreram lesão por estreitamento do canal vertebral ou lesão mista. Conclusões: a lesão por queda de peso ou estreitamento do canal vertebral provocou alterações no comportamento motor dos animais, sendo que a descompressão não trouxe melhora funcional significativa.

The aim of this study was to investigate the consequences of contusion injury of spinal cord associated with narrowing of vertebral canal on motor behavior of rats, as assessing the effect of decompression time on the neurologic recovery of the animals. Methods: male Wistar rats (n=6 per group) were divided into three experimental groups: submitted to laminectomy (T9-T10, Control Group), contusion due to weight drop (10 g from a height of 15 cm), 35 percent narrowing of the vertebral canal obtained with 0.78 mm thick polycarbonate rods and contusion injury associated with narrowing of the vertebral canal. In this last group, decompression was not performed or it was made after 24 or 72 hours of the surgery, as the animals were divided into subgroups. Rats were sacrificed seven days after surgical procedures. The motor behavior of the animals was assessed in open arena, inclined plane and by means of Basso, Beattie, and Bresnahan (BBB) locomotor rating scale, before and after 24, 48 hours and 7 days of surgical procedures. Results: contusion injury, narrowing of the spinal canal and mixed injury impaired the motor behavior of the animals. Surgical decompression (24 and 72 hours) did not improve motor recovery as assessed in open arena, BBB scale and inclined plane test. On the other hand, animals injured with weight drop showed better scores on BBB scale and higher angles in the inclined plane when compared to the ones that were injured with narrowing of the vertebral canal and mixed lesion. Conclusions: spinal cord injury by weight drop and narrowing of the vertebral canal induced alterations on the motor behavior, which did not significantly improve with decompression.

Estudiar las consecuencias de la lesión por contusión de la médula espinal, asociada al estrechamiento del canal vertebral en el comportamiento de ratas, evaluando el efecto del tiempo para la descompresión en la recuperación neurológica de los animales. Métodos: fueron utilizadas ratas Wistar machos (n=6, por grupo), subdivididos en los siguientes grupos experimentales: laminectomía (T9-T10, Grupo Control), contusión por caída de peso (10 g de peso, 15 cm de altura), estrechamiento del canal vertebral de 35 por ciento (astas de policarbonato; espesura de 0.78 mm) y contusión asociada al estrechamiento del canal vertebral. El grupo de lesión asociada fue subdividido en sin o con descompresión, 24 o 72 horas después de la cirugía. Los animales fueron sacrificados siete días después de los procedimientos quirúrgicos. La función locomotora de los animales fue evaluada por medio del teste de campo abierto, del plano inclinado y por la aplicación de la escala BBB, antes de la cirugía, 24, 72 horas y 7 días después del procedimiento quirúrgico. Resultados: la lesión por caída de peso y compresión de la médula espinal, así como la lesión mixta perjudicaron el comportamiento motor de los animales, siendo que la descompresión quirúrgica 24 y 72 horas después de la cirugía no mejoró la recuperación motora de los animales, cuando los mismos fueron evaluados en el campo abierto, en el plano inclinado y por la escala BBB. Por otro lado, los animales que sufrieron lesión medular por caída de peso presentaron mejores índices en la escala BBB y ángulos mayores en el plano inclinado, cuando comparados con aquellos que sufrieron lesión por estrechamiento del canal vertebral o la lesión mixta. Conclusiones: la lesión por caída de peso o estrechamiento del canal vertebral provocó alteraciones en el comportamiento motor de los animales, siendo que la descompresión no trajo mejoría funcional significativa.